1,3-Dicyclohexyl urea nanosuspension for intravenous steady-state delivery in rats

Journal of Experimental Nanoscience

Volumn 2, Issue 3, 2007, Pages 239-250

  Chiang, Po Chang ^a   Wahlstrom, Jan L ^a   Selbo, Jon G ^a   Zhou, Shuxia ^a   Wene, Steve P ^a   Albin, Lesley A ^a   Warren, Chad J ^a   Smith, Mark E ^a   Roberds, Steven L ^a   Ghosh, Sarbani ^a   Zhang, L Lena ^a   Pretzer, Denise K ^a  

^a PFIZER INC   (United States)

Author keywords

1,3 Dicyclohexyl urea; Infusion; Intravenous injection; Nanosuspension; Poorly soluble; Steady state

Indexed keywords

1,3 DICYCLOHEXYL UREA; ANTIHYPERTENSIVE AGENT; EPOXIDE HYDROLASE; NANOPARTICLE; SOLVENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG TARGETING; EMULSION; HYPERTENSION; IN VIVO STUDY; MALE; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STEADY STATE; SYSTOLIC BLOOD PRESSURE;

EID: 34548331724     PISSN: 17458080     EISSN: 17458099     Source Type: Journal    
DOI: 10.1080/17458080601134540     Document Type: Article

References (32)

1. Bittner, B. and Mountfield, RJ (2002) Intravenous administration of poorly soluble new drug entities in early drug discovery: The potential impact of formulation on pharmacokinetic parameters. Curr. Opi. Drug Disc. Dev., 5, p. 59.
2. Rabinow, BE (2004) Nanosuspensions in drug delivery. Nature Revi. Drug Disc., 3, p. 785.
3. Johnson, JLH and Yalkowsky, SH (2003) Prediction of precipitation-induced phlebitis: A statistical validation of an in vitro model. J. Pharm. Sci., 92, p. 1574.
4. Brazeau, GA and Fung, HL (1990) Mechanisms of creatine kinase release from isolated rat skeletal muscles damaged by propylene glycol and ethanol. J. Pharm. Sci., 79, p. 393.
5. Korttila, K., Sothman, A. and Anderson, P. (1976) Polyethylene glycol as a solvent for diazepam: Bioavailability and clinical effects after intramuscular administration, comparison of oral, intramuscular and rectal administration, and precipitation from intravenous solutions. Acta Pharmacol. Toxicol., 39, p. 104.
6. Katoh, T., Takahashi, K., Capdevila, J., Karara, A., Falck, JR, Jacobson, HR and Badr, KF (1991) Glomerular stereospecific synthesis and hemodynamic actions of 8,9-epoxyeicosatrienoic acid in rat kidney. Am. J. Physiol., 261, p. 578.
7. Lin, WK, Falck, JR and Wong, PY (1990) Effect of 14,15-epoxyeicosatrienoic acid infusion on blood pressure in normal and hypertensive rats. Biochem. Biophys. Res. Commun., 167, p. 977.
8. Imig, JD, Navar, LG, Roman, RJ, Reddy, KK and Falck, JR (1996) Actions of epoxygenase metabolites on the preglomerular vasculature. J. Am. Soc. Nephrol., 7, p. 2364.
9. Node, K., Huo, Y., Ruan, X., Yang, B., Spiecker, M., Ley, K., Zeldin, DC and Liao, JK (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science, 285, p. 1276.
10. Huse, LM, Morisseau, C., Draper, AJ, Newman, JW, Parker, C., Graham, L., Engler, MM, Hammock, BD, Zeldin, DC and Kroetz, DL (2000) Soluble Epoxide hydrolase regulates Hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res., 87, p. 992.
11. Davis, BB, David, AT, Howard, LL, Morisseau, C., Hammock, BD and Weiss, RH (2002) Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. PNAS, 99, p. 2222.
12. Ross, R. (1993) The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature (London), 362, p. 801.
13. Smith, KR, Pinkerton, KE, Watanabe, T., Pedersen, TL, Ma, SJ and Hammock, BD (2005) Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. PNAS., 102, p. 2186.
14. Akers, MJ, Fites, AL and Robison, R.L (1987) Formulation design and development of parenteral suspensions. J. Parenter. Sci. Tech., 41, p. 88.
15. Liversidge, G. and Gundy, K. (1995) Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: Absolute oral bioavailability of nanaocrystalline danazol in beagle dogs. Int. J. Pharm., 125, p. 91.
16. Liversidge, G. and Conzention, P. (1995) Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm., 125, p. 309.
17. Viernstein, J. and Stumpf, C. (1992) Similar central actions of intravenous methohexitone suspension and solution in the rabbit. J. Pharm. Pharmacol., 44, p. 66.
18. Boedeker, BH, Lojeski, EW, Kline, MD and Haynes, DH (1994) Ultra-long-duration local anesthesia produced by injection of lecithin-coated tetracaine microcrystals. J. Clin. Pharmaco., 34, p. 699.
19. Moghimi, SM, Hunter, AC and Murray, JC (2001) Long-circulating and target-specific nanoparticles: Theory to practice. Phramcol. Rev., 53, p. 283.
20. Lamprecht, A., Scháfer, U. and Lehr, C-M (2001) Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm. Res., 18, p. 788.
21. Ziller, KH and Rupprecht, HH (1990) Control of crystal growth in drug suspensions. Part 2. Influence of polymers on dissolution and crystallization during temperature cycling. Pharm. Ind., 52, p. 1017.
22. Merisko-Liversidge, E. (1996) Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm. Res., 13, p. 272.
23. Garavilla, L., Peltier, N. and Merisko-Liversidge, E. (1996) Controlling the acute hemodynamic effects associated with IV administration of particulate drug dispersion in dogs. Drug Dev. Res., 37, p. 86.
24. Borchard, G. and Kreuter, J. (1993) Interaction of serum components with poly (methyl methacrylate) nanoparticles and the resulting body distribution after intravenous injection in rats. J. Drug Target., 1, p. 15.
25. Peter, K., Leitzke, S., Diederichs, JE, Borner, K., Hahn, H., Müller, RH and Ehklers, S. (2000) Preparation of clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J. Anti. Chemo., 45, p. 77.
26. Clement, MA, Pugh, W. and Parikh, I. (1992) Tissue distribution and plasma Clearance of a novel microcrystal encapsulated flurbiprofen formulation. The Pharmacol., 34, p. 204.
27. Kipp, JE (2004) The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int. J. Pharm., 284, p. 109.
28. Kattan, J., Dorz, J-P, Couvreur, P., Marino, J-P., Boutan-Laroze, A., Rougier, P., Brault, P., Vranckx, H., Grognet, J-M, Morge, X. and Sancho-Garnier, H. (1992) Phase 1 clinical trail and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Inv. New Drugs, 10, p. 1991.
29. Haskell, RJ (2004) United State Patent.
30. Pannuti, F., Camaggie, CM, Strocchi, E. and Comparsi, R. (1987) Metroxyprogesterone acetate plasma pharmacokinetics after intravenous administration in rabbits. Cancer Chemo. Pharmacol., 19, p. 311.
31. Martin, A. (1993) Physical Pharmay, Williams & Wilkins, Baltimore, Maryland
32. Portmann, GA and Simmons, DM (1995) Microscopic determination of drug solubility in plasma and calculation of injection rates with a plasma circulatory model to prevent precipitation on intravenous injection. J. Pharm. Bio. Anal., 13, p. 1189.